| Field | Specification |
|---|---|
| Alternative names | CHIR-258 dilactic acid; TKI258 dilactic acid |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C27H33FN6O7 |
| SMILES | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Dovitinib dilactic acid, also known as CHIR-258 dilactic acid or TKI258 dilactic acid, is an orally active inhibitor of VEGF kinase. It inhibits receptor tyrosine kinases (RTKs) involved in solid and hematologic cancers and tumor angiogenesis[1]. It has the molecular formula C27H33FN6O7 and a molecular weight of 572.59 g/mol.
Physical & Chemical Properties
| CAS Number | 852433-84-2 |
|---|---|
| Molecular Formula | C27H33FN6O7 |
| Molecular Weight | 572.59 g/mol |
| SMILES | CC(O)C(O)=O.CC(O)C(O)=O.O=C1NC2=C(C(F)=CC=C2)C(N)=C1C3=NC4=CC=C(N5CCN(C)CC5)C=C4N3 |
| Signaling Pathway | Protein Tyrosine Kinase/RTK |
| Solubility | In Vitro: DMSO: ≥ 30 mg/mL (52.39 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) * "≥" means soluble, but saturation unknown. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description. Peer-reviewed publications that used this product are listed under References.
[1]. Zhu, S., et al. The Chemical Development of CHIR-258. CHIMIA International Journal for Chemistry, 60(9), 584–592.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | ≥ 30 mg/mL (52.39 mM) | use freshly opened DMSO (absorbed moisture lowers solubility) |
Data provided by the manufacturer.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
PEAK1 maintains tight junctions in intestinal epithelial cells and resists colitis by inhibiting autophagy-mediated ZO-1 degradation. Nat Commun 2025 Jul 24;16(1):6777. PMID: 40707483
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Sci Transl Med 2018 Jul 18;10(450):eaaq1093.
Jujuboside A promotes Aβ clearance and ameliorates cognitive deficiency in Alzheimer's disease through activating Axl/HSP90/PPARγ pathway. Theranostics 2018 Jul 30;8(15):4262-4278.
Acta Pharm Sin B. 2026 Feb 10.
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer. NPJ Precis Oncol 2021 Jul 16;5(1):66. PMID: 34272467
An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness. Front Cell Dev Biol 2020 May 7:8:287. PMID: 32457900
Activation of Gcn2 by small molecules designed to be inhibitors. J Biol Chem 2023 Apr;299(4):104595. PMID: 36898579
Impact of anticancer drugs on human Tenon's fibroblast proliferation: implications for glaucoma surgery. BMJ Open Ophthalmol 2026 Jan 12;11(1):e002307. PMID: 41526033
Preprints. 2026 Jun 19.
University of Düsseldorf. 2024.
